Malmanu it seems the significance of a possible cancer treatment is lost on you.This isn't your average biotech company targeting wrinkles on faces, this is serious business and the market knows it.
PV1 Provaris tells ASX non-binding MOUs are still material to share prices in somewhat fiery compliance response